nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—ADRA1A—polycystic ovary syndrome	0.811	1	CbGaD
Apraclonidine—Upset stomach—Metformin—polycystic ovary syndrome	0.00247	0.0816	CcSEcCtD
Apraclonidine—Clonidine—ADRA1D—polycystic ovary syndrome	0.00232	0.368	CrCbGaD
Apraclonidine—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.002	0.066	CcSEcCtD
Apraclonidine—Clonidine—ADRA1B—polycystic ovary syndrome	0.00198	0.314	CrCbGaD
Apraclonidine—Clonidine—ADRA1A—polycystic ovary syndrome	0.00133	0.211	CrCbGaD
Apraclonidine—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00105	0.0347	CcSEcCtD
Apraclonidine—Abdominal discomfort—Metformin—polycystic ovary syndrome	0.000975	0.0322	CcSEcCtD
Apraclonidine—Infestation—Metformin—polycystic ovary syndrome	0.000907	0.0299	CcSEcCtD
Apraclonidine—Infestation NOS—Metformin—polycystic ovary syndrome	0.000907	0.0299	CcSEcCtD
Apraclonidine—Bradycardia—Metformin—polycystic ovary syndrome	0.000829	0.0273	CcSEcCtD
Apraclonidine—Rhinitis—Metformin—polycystic ovary syndrome	0.000816	0.0269	CcSEcCtD
Apraclonidine—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000802	0.0264	CcSEcCtD
Apraclonidine—Eye disorder—Metformin—polycystic ovary syndrome	0.000761	0.0251	CcSEcCtD
Apraclonidine—Angiopathy—Metformin—polycystic ovary syndrome	0.000739	0.0244	CcSEcCtD
Apraclonidine—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000734	0.0242	CcSEcCtD
Apraclonidine—Erythema—Metformin—polycystic ovary syndrome	0.000709	0.0234	CcSEcCtD
Apraclonidine—Dysgeusia—Metformin—polycystic ovary syndrome	0.000694	0.0229	CcSEcCtD
Apraclonidine—Clonidine—CYP1A1—polycystic ovary syndrome	0.000678	0.108	CrCbGaD
Apraclonidine—Vision blurred—Metformin—polycystic ovary syndrome	0.000668	0.022	CcSEcCtD
Apraclonidine—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000657	0.0217	CcSEcCtD
Apraclonidine—Malaise—Metformin—polycystic ovary syndrome	0.000639	0.0211	CcSEcCtD
Apraclonidine—Syncope—Metformin—polycystic ovary syndrome	0.000635	0.021	CcSEcCtD
Apraclonidine—Palpitations—Metformin—polycystic ovary syndrome	0.000626	0.0207	CcSEcCtD
Apraclonidine—Myalgia—Metformin—polycystic ovary syndrome	0.000603	0.0199	CcSEcCtD
Apraclonidine—Chest pain—Metformin—polycystic ovary syndrome	0.000603	0.0199	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000599	0.0198	CcSEcCtD
Apraclonidine—Discomfort—Metformin—polycystic ovary syndrome	0.000596	0.0197	CcSEcCtD
Apraclonidine—Oedema—Metformin—polycystic ovary syndrome	0.000578	0.0191	CcSEcCtD
Apraclonidine—Infection—Metformin—polycystic ovary syndrome	0.000575	0.0189	CcSEcCtD
Apraclonidine—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000567	0.0187	CcSEcCtD
Apraclonidine—Skin disorder—Metformin—polycystic ovary syndrome	0.000562	0.0185	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000527	0.0174	CcSEcCtD
Apraclonidine—Paraesthesia—Metformin—polycystic ovary syndrome	0.000519	0.0171	CcSEcCtD
Apraclonidine—Dyspnoea—Metformin—polycystic ovary syndrome	0.000516	0.017	CcSEcCtD
Apraclonidine—Somnolence—Metformin—polycystic ovary syndrome	0.000514	0.017	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000499	0.0165	CcSEcCtD
Apraclonidine—Fatigue—Metformin—polycystic ovary syndrome	0.000499	0.0164	CcSEcCtD
Apraclonidine—Constipation—Metformin—polycystic ovary syndrome	0.000495	0.0163	CcSEcCtD
Apraclonidine—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000477	0.0157	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000473	0.0156	CcSEcCtD
Apraclonidine—Abdominal pain—Metformin—polycystic ovary syndrome	0.000457	0.0151	CcSEcCtD
Apraclonidine—Asthenia—Metformin—polycystic ovary syndrome	0.000415	0.0137	CcSEcCtD
Apraclonidine—Pruritus—Metformin—polycystic ovary syndrome	0.000409	0.0135	CcSEcCtD
Apraclonidine—Diarrhoea—Metformin—polycystic ovary syndrome	0.000396	0.0131	CcSEcCtD
Apraclonidine—Dizziness—Metformin—polycystic ovary syndrome	0.000382	0.0126	CcSEcCtD
Apraclonidine—Vomiting—Metformin—polycystic ovary syndrome	0.000368	0.0121	CcSEcCtD
Apraclonidine—Dermatitis—Metformin—polycystic ovary syndrome	0.000364	0.012	CcSEcCtD
Apraclonidine—Headache—Metformin—polycystic ovary syndrome	0.000362	0.0119	CcSEcCtD
Apraclonidine—Nausea—Metformin—polycystic ovary syndrome	0.000344	0.0113	CcSEcCtD
Apraclonidine—ADRA2C—Metabolism—AKR1C1—polycystic ovary syndrome	3.97e-05	0.000261	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRA1B—polycystic ovary syndrome	3.95e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.95e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR ligand binding—POMC—polycystic ovary syndrome	3.95e-05	0.00026	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.92e-05	0.000258	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HMMR—polycystic ovary syndrome	3.92e-05	0.000258	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.87e-05	0.000255	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INHBB—polycystic ovary syndrome	3.85e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FST—polycystic ovary syndrome	3.85e-05	0.000253	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	3.83e-05	0.000252	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.8e-05	0.00025	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.79e-05	0.000249	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.77e-05	0.000248	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LHB—polycystic ovary syndrome	3.76e-05	0.000247	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HSD3B1—polycystic ovary syndrome	3.74e-05	0.000246	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3.69e-05	0.000243	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.67e-05	0.000241	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SULT2A1—polycystic ovary syndrome	3.65e-05	0.00024	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—IGF1—polycystic ovary syndrome	3.64e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—AKT2—polycystic ovary syndrome	3.63e-05	0.000239	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.6e-05	0.000237	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FST—polycystic ovary syndrome	3.59e-05	0.000236	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	3.57e-05	0.000235	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.55e-05	0.000234	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.55e-05	0.000234	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.55e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—RRM2—polycystic ovary syndrome	3.54e-05	0.000233	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FSHR—polycystic ovary syndrome	3.52e-05	0.000232	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SCT—polycystic ovary syndrome	3.52e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LHB—polycystic ovary syndrome	3.51e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.51e-05	0.000231	CbGpPWpGaD
Apraclonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—polycystic ovary syndrome	3.5e-05	0.00023	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—ADRB2—polycystic ovary syndrome	3.47e-05	0.000229	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—SERPINE1—polycystic ovary syndrome	3.45e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR ligand binding—POMC—polycystic ovary syndrome	3.45e-05	0.000227	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNRH1—polycystic ovary syndrome	3.43e-05	0.000226	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.43e-05	0.000225	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—YAP1—polycystic ovary syndrome	3.41e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—LHB—polycystic ovary syndrome	3.41e-05	0.000224	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—IGF1—polycystic ovary syndrome	3.4e-05	0.000223	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—AKT2—polycystic ovary syndrome	3.39e-05	0.000223	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.36e-05	0.000221	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—HSD3B2—polycystic ovary syndrome	3.33e-05	0.000219	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKR1C1—polycystic ovary syndrome	3.32e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.31e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—GNAS—polycystic ovary syndrome	3.31e-05	0.000218	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—FGF18—polycystic ovary syndrome	3.3e-05	0.000217	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SCT—polycystic ovary syndrome	3.29e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NAMPT—polycystic ovary syndrome	3.28e-05	0.000216	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FSHR—polycystic ovary syndrome	3.28e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RBP4—polycystic ovary syndrome	3.27e-05	0.000215	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—ADRB2—polycystic ovary syndrome	3.24e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP11A1—polycystic ovary syndrome	3.24e-05	0.000213	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKR1C1—polycystic ovary syndrome	3.23e-05	0.000212	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—SERPINE1—polycystic ovary syndrome	3.22e-05	0.000212	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.22e-05	0.000212	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR ligand binding—POMC—polycystic ovary syndrome	3.21e-05	0.000211	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.18e-05	0.000209	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FST—polycystic ovary syndrome	3.14e-05	0.000207	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTNR1B—polycystic ovary syndrome	3.14e-05	0.000206	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	3.12e-05	0.000205	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB3—polycystic ovary syndrome	3.1e-05	0.000204	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FGF18—polycystic ovary syndrome	3.08e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.08e-05	0.000203	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LHB—polycystic ovary syndrome	3.07e-05	0.000202	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKR1C3—polycystic ovary syndrome	3.06e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RBP4—polycystic ovary syndrome	3.06e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—YAP1—polycystic ovary syndrome	3.05e-05	0.000201	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GAB1—polycystic ovary syndrome	3.01e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP17A1—polycystic ovary syndrome	3.01e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—GNAS—polycystic ovary syndrome	3.01e-05	0.000198	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNRH1—polycystic ovary syndrome	3e-05	0.000197	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRA1A—polycystic ovary syndrome	3e-05	0.000197	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SULT2A1—polycystic ovary syndrome	2.97e-05	0.000195	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FST—polycystic ovary syndrome	2.92e-05	0.000192	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.9e-05	0.000191	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.9e-05	0.000191	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.9e-05	0.000191	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.88e-05	0.00019	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INSR—polycystic ovary syndrome	2.88e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—RRM2—polycystic ovary syndrome	2.87e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SCT—polycystic ovary syndrome	2.87e-05	0.000189	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—YAP1—polycystic ovary syndrome	2.85e-05	0.000188	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LHB—polycystic ovary syndrome	2.85e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.84e-05	0.000187	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GAB1—polycystic ovary syndrome	2.81e-05	0.000185	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.78e-05	0.000183	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—YAP1—polycystic ovary syndrome	2.77e-05	0.000182	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—IGF1—polycystic ovary syndrome	2.76e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT2—polycystic ovary syndrome	2.76e-05	0.000181	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.74e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.74e-05	0.00018	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.7e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGF18—polycystic ovary syndrome	2.69e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.69e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.69e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INSR—polycystic ovary syndrome	2.69e-05	0.000177	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RBP4—polycystic ovary syndrome	2.67e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	2.67e-05	0.000176	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PGR—polycystic ovary syndrome	2.67e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	2.66e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.66e-05	0.000175	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.64e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.63e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	2.63e-05	0.000173	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	2.62e-05	0.000172	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—TH—polycystic ovary syndrome	2.6e-05	0.000171	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.56e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.55e-05	0.000168	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—SLC2A4—polycystic ovary syndrome	2.53e-05	0.000167	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.52e-05	0.000166	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	2.5e-05	0.000165	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—YAP1—polycystic ovary syndrome	2.49e-05	0.000164	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PGR—polycystic ovary syndrome	2.49e-05	0.000164	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	2.48e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	2.48e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GHRL—polycystic ovary syndrome	2.48e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PLAT—polycystic ovary syndrome	2.48e-05	0.000163	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GAB1—polycystic ovary syndrome	2.46e-05	0.000162	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	2.44e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.44e-05	0.000161	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.39e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP19A1—polycystic ovary syndrome	2.38e-05	0.000157	CbGpPWpGaD
Apraclonidine—ADRA2B—Hemostasis—VEGFA—polycystic ovary syndrome	2.37e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ATF1—polycystic ovary syndrome	2.37e-05	0.000156	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INSR—polycystic ovary syndrome	2.35e-05	0.000155	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	2.32e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GHRL—polycystic ovary syndrome	2.32e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PLAT—polycystic ovary syndrome	2.32e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.31e-05	0.000152	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.3e-05	0.000151	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	2.29e-05	0.00015	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.23e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—POMC—polycystic ovary syndrome	2.23e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2C—Hemostasis—VEGFA—polycystic ovary syndrome	2.22e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ATF1—polycystic ovary syndrome	2.21e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.2e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	2.19e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NGFR—polycystic ovary syndrome	2.18e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PGR—polycystic ovary syndrome	2.18e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—POMC—polycystic ovary syndrome	2.17e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PRL—polycystic ovary syndrome	2.16e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.15e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT2—polycystic ovary syndrome	2.14e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—GNAS—polycystic ovary syndrome	2.13e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—TH—polycystic ovary syndrome	2.12e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT2—polycystic ovary syndrome	2.08e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.08e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	2.06e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.05e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.04e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NGFR—polycystic ovary syndrome	2.04e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—POMC—polycystic ovary syndrome	2.03e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NCOR1—polycystic ovary syndrome	2.03e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	2.02e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	2.02e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	2.02e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PRL—polycystic ovary syndrome	2.02e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.95e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.95e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	1.93e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.93e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—CYP1A1—polycystic ovary syndrome	1.92e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.92e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—GNAS—polycystic ovary syndrome	1.9e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.88e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.88e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.88e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.87e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.81e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.81e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	1.8e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.79e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—MTHFR—polycystic ovary syndrome	1.79e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.78e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NRG1—polycystic ovary syndrome	1.78e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—GNAS—polycystic ovary syndrome	1.78e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.77e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	1.77e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.75e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.74e-05	0.000115	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	1.73e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.7e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.69e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.68e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NRG1—polycystic ovary syndrome	1.66e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.66e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.65e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	1.64e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	1.64e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.58e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	1.56e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.56e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.55e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.52e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—LEP—polycystic ovary syndrome	1.49e-05	9.81e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.48e-05	9.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	1.45e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.45e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PPARG—polycystic ovary syndrome	1.45e-05	9.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.44e-05	9.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—POMC—polycystic ovary syndrome	1.43e-05	9.42e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS2—polycystic ovary syndrome	1.42e-05	9.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—INS—polycystic ovary syndrome	1.42e-05	9.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—LEP—polycystic ovary syndrome	1.39e-05	9.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.38e-05	9.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.35e-05	8.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IRS1—polycystic ovary syndrome	1.33e-05	8.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—POMC—polycystic ovary syndrome	1.28e-05	8.43e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—INS—polycystic ovary syndrome	1.27e-05	8.38e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.24e-05	8.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IRS1—polycystic ovary syndrome	1.24e-05	8.18e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—polycystic ovary syndrome	1.23e-05	8.11e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT2—polycystic ovary syndrome	1.23e-05	8.1e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	1.22e-05	8.01e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—POMC—polycystic ovary syndrome	1.2e-05	7.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—INS—polycystic ovary syndrome	1.19e-05	7.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	1.18e-05	7.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.17e-05	7.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	1.16e-05	7.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	1.16e-05	7.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—INS—polycystic ovary syndrome	1.16e-05	7.61e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—polycystic ovary syndrome	1.15e-05	7.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT2—polycystic ovary syndrome	1.15e-05	7.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	1.13e-05	7.44e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.09e-05	7.19e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.09e-05	7.15e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	1.05e-05	6.88e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	1.04e-05	6.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	1.01e-05	6.64e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	1.01e-05	6.62e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	1.01e-05	6.62e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	9.72e-06	6.39e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	9.67e-06	6.36e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.56e-06	6.29e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—polycystic ovary syndrome	9.42e-06	6.2e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	9.35e-06	6.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	9.34e-06	6.15e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.88e-06	5.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—polycystic ovary syndrome	8.8e-06	5.79e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.05e-06	5.3e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.7e-06	5.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.52e-06	4.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	7.15e-06	4.7e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.57e-06	4.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.11e-06	4.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—polycystic ovary syndrome	5.57e-06	3.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—polycystic ovary syndrome	5.2e-06	3.42e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	4.55e-06	2.99e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	4.22e-06	2.78e-05	CbGpPWpGaD
